- Generic name
- Clobazam
- Strength
- 10 mg
- Dosage form
- Tablet
- Manufactured by
- Synovia Pharma PLC.
Ficlozam Tablet
About Ficlozam 10 mg Tablet
Ficlozam is a 10 mg tablet from Synovia Pharma PLC. It contains clobazam, a benzodiazepine medicine used for anxiety and certain other conditions. A doctor decides whether it is suitable and how it should be taken.
There are 21 brands of Clobazam listed in Bangladesh. The lowest listed price is Nebium 10 mg Tablet at ৳ 2.55 per unit.
What is Ficlozam 10 mg Tablet?
Ficlozam is a tablet made by Synovia Pharma PLC. Each tablet contains 10 mg of clobazam, which belongs to a group of medicines called benzodiazepines. It is used in the treatment of acute and chronic anxiety states, where symptoms can include tension, restlessness, irritability, sleep disturbances from emotional causes and emotional instability. It may also be used in other conditions as decided by a doctor. Clobazam works on the brain and nervous system. Because it can affect alertness and reaction time, the doctor will consider this when prescribing it. The dose and length of treatment are set by the doctor for each person.
Uses of Ficlozam
Ficlozam is used for anxiety that is short-term (acute) or long-lasting (chronic). In anxiety, people may feel tense, restless, irritable or emotionally unstable, and may have sleep problems caused by emotions. It is also used for certain physical symptoms that are linked to psychological and emotional factors, such as problems in the heart and blood vessels or the stomach and gut. A doctor may prescribe it for other reasons as well. Only a doctor can decide if this medicine is right for a particular person.
How to use Ficlozam
Take Ficlozam exactly as your doctor tells you. The doctor chooses the dose and how long you take it, based on your condition, how severe it is and how you respond. The aim is to use the lowest dose that works for you. Swallow the tablet as directed. Because clobazam can make you sleepy or slow your reactions, be careful when driving or doing tasks that need alertness until you know how it affects you. Do not stop taking it suddenly; ask your doctor first. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Ficlozam
Common side effects include sleepiness, especially at the start of treatment or with higher doses. Other common effects are sedation, dizziness, trouble concentrating, slow or slurred speech, headache, tremor and problems with coordination. Some people may feel irritable, aggressive, restless or depressed, and drug tolerance can occur with long use. Less common effects include double vision. Serious skin reactions have been reported with clobazam. Call your doctor right away if you notice a rash, blistering or peeling skin, or if you feel very sleepy or unwell.
Safety and precautions
Do not take Ficlozam if you are allergic to clobazam or any of its ingredients. It must not be used by people with myasthenia gravis, severe breathing problems, sleep apnoea, severe liver problems, or by women who are breast-feeding. It is not recommended in the first trimester of pregnancy or in women who could become pregnant and are not using contraception. Tell your doctor if you are pregnant, planning pregnancy or breast-feeding. Also tell your doctor if you have liver or kidney problems, breathing problems, or if you drink alcohol or take other medicines that make you sleepy. Children should only be given benzodiazepines after careful assessment by a doctor.
Frequently asked questions
What side effects should I watch for, and when should I call the doctor?
Watch for sleepiness, dizziness, slow speech, poor coordination, or changes in mood such as irritability or depression. Call your doctor right away if you have a skin rash, blistering or peeling, or if you feel very sleepy or unwell. Serious skin reactions need urgent medical attention.
What is Ficlozam used for and what kind of medicine is it?
Ficlozam is a benzodiazepine medicine. It is used for acute and chronic anxiety states, including symptoms like tension, restlessness, irritability, sleep problems from emotional causes, and emotional instability. It may also be used for certain physical symptoms linked to psychological factors. Your doctor will decide if it is suitable for you.
Who should avoid Ficlozam or ask the doctor first?
Do not use it if you are allergic to clobazam or its ingredients, or if you have myasthenia gravis, severe breathing problems, sleep apnoea, severe liver problems, or if you are breast-feeding. Ask your doctor first if you are pregnant or planning pregnancy, have liver or kidney problems, or take other medicines that cause sleepiness.
Can I stop taking Ficlozam suddenly?
No, do not stop taking Ficlozam suddenly without talking to your doctor. Stopping suddenly can cause problems. Your doctor will tell you how to reduce the dose safely. Always follow your doctor's instructions about how long to take it and how to stop.
Indications
In patients with depression or anxiety associated with depression, Clobazam must be used only in conjunction with adequate concomitant treatment. Use of benzodiazepines alone, can precipitate suicide in such patients. Before treatment of anxiety states associated with emotional instability, it must first be determined whether the patient suffers from a depressive disorder requiring adjunctive or different treatment.
In patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for adjunctive, i.e. not for primary treatment.
As adjunctive therapy in patients with epilepsy who are not adequately stabilized with their anticonvulsant monotherapy.
Pharmacology
Dosage & Administration
Treatment of anxiety states-
Adults and adolescents over 15 years of age: The initial dose is usually 20 mg clobazam daily. If necessary, the daily dose may be increased. Generally, it is recommended that a total daily dose of 30 mg is not exceeded.Elderly: Increased responsiveness and higher susceptibility to adverse effects may be present in elderly patients and require low initial doses and gradual dose increments under careful observation. A maintenance dose of 10 to 15 mg clobazam daily is frequently sufficient.
Children from 3 to 15 years of age: Increased responsiveness and higher susceptibility to adverse effects may be present in children and require low initial doses and gradual dose increments under careful observation. A daily dose of 5 to 10 mg clobazam is frequently sufficient. Benzodiazepines must not be given to children without careful assessment of the need for their use.
Secondary dosage adjustment: After the improvement of the symptoms, the dose may be reduced.
Timing of doses: If the dose is to be spread throughout the day, it is recommended that the larger portion be taken in the evening.
Duration of treatment: The duration of treatment must be as short as possible. The patient must be reassessed after a period not exceeding 4 weeks and regularly thereafter in order to evaluate the need for continued treatment, especially where the patient is free of symptoms. Generally, the overall duration of treatment (i.e. including tapering-of process) must not exceed 8 to 12 weeks. In certain cases, extension beyond the maximum treatment period may be necessary; treatment must not be extended without a re-evaluation of the patient's status using special expertise. It is strongly recommended that prolonged periods of uninterrupted treatment be avoided, since they may lead to dependence.
Discontinuation of treatment: It is strongly recommended that after prolonged treatment clobazam is not withdrawn suddenly but rather that the dose is reduced gradually under medical supervision; otherwise, withdrawal symptoms may occur.
Treatment of epilepsy in combination with one or more other anticonvulsants-
Adults and adolescents over 15 years of age: It is recommended that administration be started at small doses (5 to 15 mg daily), if necessary, increasing the dose gradually to a maximum daily dose of about 80 mg.Children from 3 to 15 years of age: It is recommended that normally treatment be started at 5 mg daily. A maintenance dose of 0.3 to 1.0 mg/kg body weight daily is usually sufficient. Higher susceptibility to adverse effects may be present in children and require gradual dose increments under careful observation; Benzodiazepines must not be given to children without careful assessment of the need for their use.
Elderly: Higher susceptibility to adverse effects may be present in elderly patients and require low initial doses and gradual dose increments under careful observation.
Timing of doses: If the dose is spread throughout the day, it is recommended that the larger portion be taken in the evening. Doses of up to 30 mg clobazam can also be administered as a single evening dose.
Duration of treatment: The patient must be re-assessed after a period not exceeding 4 weeks and regularly thereafter in order to evaluate the need for continued treatment.
Discontinuation of treatment: At the end of treatment- to include cases in which response to therapy has been poor- it is strongly recommended that clobazam is not withdrawn suddenly but rather that the dose is reduced gradually; otherwise an increased susceptibility to seizures as well as other withdrawal symptoms may occur.
Interaction
Central nervous system depressant drugs: Especially when clobazam is administered in higher doses, a mutually potentiating effect is to be expected if other central nervous system depressant drugs (such as antipsychotics, anxiolytics, certain antidepressant agents, anticonvulsant drugs, sedative antihistamines, anaesthetics, hypnotics or narcotic analgesics, or other sedatives) are taken at the same time. Special caution is also necessary when clobazam is administered in cases of intoxication with such substances or with lithium.
Opioids: The concomitant use of benzodiazepines, including clobazam, and opioids increases the risk of sedation, respiratory depression, coma, and death because of the additive CNS depressant effect. Limit dosage and duration of concomitant use of benzodiazepines and opioids.
Anticonvulsants: If clobazam is administered simultaneously with anticonvulsants in the treatment of epilepsy, the dosage must be adjusted under regular medical supervision (EEG monitoring), as there may be interactions with the patient's basic anticonvulsant medication. In patients receiving concomitant treatment with valproic acid, there may be a slight to moderate rise in plasma valproic acid concentration. Phenytoin plasma levels may rise if patients receive concomitant treatment with clobazam. Where possible, it is recommended that blood levels of concomitantly administered valproic acid or phenytoin be monitored. Carbamazepine and phenytoin may cause an increase in the metabolic conversion of clobazam to the active metabolite N-desmethyl clobazam. Stiripentol increases plasma levels of clobazam and its active metabolite N-desmethylclobazam, through inhibition of CYP3A and CYP2C19. Monitoring of blood levels is recommended, prior to initiation of stiripentol, and then once new steady-state concentration has been reached, i.e. after 2 weeks approximately.
Narcotic analgesics: If clobazam is used concomitantly with narcotic analgesics, possible euphoria may be enhanced; this may lead to increased psychological dependence.
Muscle relaxants: The effects of muscle relaxants and nitrous oxide may be enhanced.
CYP 2C19 inhibitors: Strong and moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam (N-CLB), the active metabolite of clobazam. Dosage adjustment of clobazam may be necessary when co-administered with strong CYP2C19 inhibitors (e.g., cannabidiol containing medicinal products, fuconazole, fuvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g. omeprazole).
CYP 2D6 substrates: Clobazam is a weak CYP2D6 inhibitor. Dose adjustment of drugs metabolized by CYP2D6 (e.g. dextromethorphan, pimozide, paroxetine, nebivolol) may be necessary.
Contraindications
- In patients with hypersensitivity to clobazam or any of the excipients of Clobazam.
- In patients with myasthenia gravis (risk of aggravation of muscle weakness).
- In patients with severe respiratory insufciency (risk of deterioration).
- In patients with sleep apnoea syndrome (risk of deterioration).
- In patients with severe impairment of liver function (risk of precipitating encephalopathy).
- In breast-feeding women Benzodiazepines must not be given to children without careful assessment of the need for their use.
- Clobazam must not be used in children between the ages of 6 months and 3 years, other than in exceptional cases for anticonvulsant treatment where there is a compelling indication.
Side Effects
Psychiatric disorders: Common: irritability, aggression, restlessness, depression (pre-existing depression may be unmasked), drug tolerance (especially during prolonged use), agitation.
Nervous system disorders: Very common: somnolence, especially at the beginning of treatment and when higher doses are used; Common: sedation, dizziness, disturbance in attention, slow speech/dysarthria/ speech disorder (particularly with high doses or in long-term treatment, and are reversible), headache, tremor, ataxia.
Eye Disorders: Uncommon: diplopia (particularly with high doses or in long-term treatment and is reversible)
Respiratory, thoracic and mediastinal disorders: Not known: respiratory depression respiratory failure (particularly in patients with pre-existing compromised respiratory function e.g. in patients with bronchial asthma or brain damage)
Gastrointestinal disorders: Common: dry mouth, nausea, constipation
Skin and subcutaneous disorders: Uncommon: rash; Not known: photosensitivity reaction urticaria; Steven Johnson syndrome, toxic epidermal necrolysis (including some cases with fatal outcome);
Musculoskeleteal and connective tissue disorders: Not known: muscle spasms, muscle weakness
General disorders and administration site conditions: Very common: fatigue, especially at the beginning of treatment and when higher doses are used. Not known: slow response to stimuli, hypothermia
Investigations: Uncommon: weight increased (particularly with high doses or in long-term treatment).
Pregnancy & Lactation
Lactation: Clobazam must not be used in breastfeeding women, since clobazam passes into breast milk.
Precautions & Warnings
Respiratory depression: Clobazam can cause respiratory depression, especially if administered in high doses. Therefore in patients with chronic or acute respiratory insufficiency, respiratory function must be monitored and a dose reduction may be necessary. Clobazam is contraindicated in patients with severe respiratory insufficiency.
Muscle weakness: Clobazam can cause muscle weakness. Clobazam is contraindicated in patients with myasthenia gravis.
Renal and hepatic impairment: In patients with impairment of renal or hepatic function, responsiveness to clobazam and susceptibility to adverse effects are increased, and a dose reduction may be necessary. In long-term treatment, renal and hepatic function must be checked regularly.
Elderly patients: In the elderly, due to the increased sensitivity to adverse reactions such as drowsiness, dizziness, muscle weakness, there is an increased risk of fall that may result in serious injury. A dose reduction is recommended.
Tolerance in epilepsy: In the treatment of epilepsy with benzodiazepines- including Clobazam, consideration must be given to the possibility of a decrease in anticonvulsant efficacy (development of tolerance) in the course of treatment.
CYP2C19 poor metabolizers: In patients who are CYP2C19 poor metabolizers, levels of the active metabolite N-desmethylclobazam are expected to be increased as compared to extensive metabolizers. Dosage adjustment of clobazam may be necessary (e.g. low starting dose with careful dose titration).
Suicidality: Several epidemiological studies show an increased incidence of suicide and suicide attempt in patients with or without depression, treated with other benzodiazepines and hypnotics. There are very limited data available for clobazam in these studies. Cases of suicidal behavior have been reported with clobazam in post-marketing surveillance. All of these cases had confounding factors.
Concomitant use of CYP2C19 inhibitors: The concomitant use of clobazam with CYP2C19 inhibitors, including cannabidiol containing medicinal products, dietary supplements and recreational products may result in increased exposure to N-desmethylclobazam (NCLB). Such increases might lead to increased adverse effects, such as somnolence and sedation. When used with medicinal products that are CYP2C19 inhibitors dosage adjustment of clobazam may be necessary. Dietary supplements and recreational products containing cannabidiol must not be taken in combination with clobazam as they contain unknown quantities of cannabidiol and are of variable quality
Storage Conditions
Alternative brands of Clobazam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.